Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 5/20 | 0.46 |
| ▸ | JAK1 | P23458 | 5/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.43 |
| ▸ | GRIN2B | Q13224 | 5/20 | 0.42 |
| ▸ | TYK2 | P29597 | 4/20 | 0.42 |
| ▸ | JAK3 | P52333 | 4/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | TRPC3 | Q13507 | 1/20 | 0.40 |
| ▸ | TRPC7 | Q9HCX4 | 1/20 | 0.40 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29854457 | 0.90 | JAK2 (0.47) | JAK2JAK1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL28628199 | 0.85 | TNK2 (0.48) | JAK2JAK1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL28628197 | 0.85 | TNK2 (0.48) | JAK2JAK1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL28722982 | 0.85 | JAK2 (0.46) | JAK2JAK1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL21056239 | 0.85 | JAK2 (0.46) | JAK2JAK1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL27188701 | 0.83 | TNK2 (0.35) | — | |
| SCHEMBL27188702 | 0.83 | TNK2 (0.35) | — | |
| SCHEMBL14654246 | 0.80 | JAK2 (0.47) | JAK2JAK1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL26791385 | 0.80 | TNK2 (0.47) | JAK2JAK1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL29854441 | 0.79 | SMN1; SMN2 (0.44) | JAK2JAK1SMN1; SMN2NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240109896-A1 | FGFR KINASE INHIBITOR AND USE THEREOF | YA THERAPEUTICS INC (CN) | 2024-04-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240109896-A1 | FGFR KINASE INHIBITOR AND USE THEREOF | FGFR1, FGFR2, FGFR3 | JAK2 11/4885JAK1 17/4885SMN1; SMN2 2834/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.